Wells Fargo raises target for Editas Medicine stock from USD 4.00 to USD 6.00

Published on 10/20/2026 at 20:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 11.89 million versus USD 2.85 million expected. Editas Medicine stock costs EUR 2.34 on October 20, 2026 at 8:20 p.m. CEST.

Wells Fargo target and reporting date

Wells Fargo raised its Editas Medicine target from USD 4.00 to USD 6.00 on October 8, 2026.
Second-quarter 2026 revenue reached USD 11.89 million against USD 2.85 million expected.
Editas Medicine stock costs EUR 2.34 at Lang & Schwarz on October 20, 2026 at 8:20 p.m. CEST.

EDIT, US28106W1036, Illustration mit AI erstellt.

Editas Medicine stock (ISIN US28106W1036) is being reassessed after Wells Fargo raised its target from USD 4.00 to USD 6.00 on October 8, 2026. According to MarketBeat, the firm also upgraded the stock from equal weight to overweight. Editas Medicine was trading at EUR 2.34 at Lang & Schwarz on October 20, 2026 at 8:20 p.m. CEST.

Second-quarter revenue beat expectations

Editas Medicine reported USD 11.89 million in second-quarter 2026 revenue, compared with USD 2.85 million expected. The company also reported an adjusted per-share loss of USD 0.15, versus a consensus loss of USD 0.27, according to MarketBeat in its October 8, 2026 report.

What does the target imply?

Wells Fargo's USD 6.00 target is 129.01 percent above the USD 2.62 Nasdaq price on October 20, 2026 at 2:26 p.m. EDT. That comparison uses the US-listed share price and keeps the analyst target separate from the euro quotation used for German-market investors.

Price position and trading activity

Editas Medicine had a USD 403.1 million market capitalization and traded 1,403,796 shares on October 20, 2026. Its USD 1.66 to USD 4.21 52-week range places the current Nasdaq price inside a wide biotechnology trading band. The company operates in healthcare biotechnology and develops CRISPR-based genomic medicines.

Dates for the next report

The next reporting date is estimated for November 9, 2026, before the market opens. The conference call is scheduled for November 3, 2026 at 4:00 p.m. ET, according to MarketBeat. The same schedule lists consensus estimates of USD 4.54 million in revenue and a USD 0.21 per-share loss for the third quarter of 2026.

Stock remains tied to clinical milestones

Editas Medicine's valuation continues to depend on clinical development and the company's ability to turn its gene-editing platform into approved treatments. For investors, the contrast between USD 11.89 million of second-quarter revenue and the USD 4.54 million third-quarter consensus estimate makes the November update the next quantified test.

The euro quotation was EUR 2.34 at Lang & Schwarz on October 20, 2026 at 8:20 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Editas Medicine stock.